Skip to content

Therapeutic Research in Multiple Myeloma

UARK 91-004 Therapeutic Research in Multiple Myeloma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00572338
Enrollment
6388
Registered
2007-12-13
Start date
2003-08-31
Completion date
2015-03-31
Last updated
2015-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

The purpose of this study is to learn how myeloma cells grow and become a cancer, how to distinguish them from normal cells and how to eliminate these cells selectively.

Detailed description

Participating in this study will require that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of your multiple myeloma. Bone marrow/peripheral blood/tissue samples will be collected for research purposes, as well as testing for genetic traits of Castleman's disease if you consent to this study. In addition, data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.

Interventions

OTHERNo drugs are involved

No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.

Sponsors

University of Arkansas
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any subject evaluated for a MIRT protocol

Exclusion criteria

* Subjects who have not been evaluated for a MIRT protocol

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026